Advanced Solid Cancer Clinical Trial
Official title:
A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor
This was an open-label Phase I study. The primary objective of the study was to assess safety, tolerability, efficacy, and pharmacokinetic characteristics of BPI-16350 in different dose groups.
The study was divided into two sections: dose escalation section and expanded enrollment section. In dose escalation section, BPI-16350 were administered orally once daily (QD) to patients with locally advanced or metastatic solid tumors in different dose levels.The study was designed to evaluate the safety, tolerability, and pharmacokinetics of single dose and multiple doses of BPI-16350. In expanded enrollment section, based on the results of dose escalation section, BPI-16350 were administered orally to patients with locally advanced or metastatic solid tumors, to further evaluate the safety, tolerability, and pharmacokinetics of BPI-16350. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01416623 -
A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Recruiting |
NCT03618043 -
Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Recruiting |
NCT03917043 -
APG-2449 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Terminated |
NCT03884517 -
Clinical Trial of BAT8003 (for Injection) for Patients With Advanced Epithelial Cancer
|
Phase 1 | |
| Recruiting |
NCT04877717 -
A Study of SHR-A1904 in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Recruiting |
NCT05770310 -
A Phase I Study Of JS015 in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05947474 -
ORB-011 In Patients With Advanced Solid Tumors
|
Phase 1 |